author-photo

Catherine Bouard

Novartis

14

Papers

56

Citations

Citation Trend

Filter By

Papers (11) Sort By

Journal Conference Others

Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update.

2021 Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

2020 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (17)
ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia

2020 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study.

2020 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (1)
ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
ENESTop 192-Weeks Results: Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (2)
A subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohort

2019 Hematology, Transfusion and Cell Therapy
Show All
- Source
- Cite
- Save
Citations (1)
Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib

2018 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (2)
Primary Analysis of JUMP, a Phase 3b, Expanded-Access Study Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis (N = 2233)

2017 Blood
Show All
- Source
- Cite
- Save
Citations (7)